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Acute Heart Failure
Syndromes and Coronary Perfusion
Nirat Beohar, MD, FACC,* Ata K. Erdogan, MD,* Daniel C. Lee, MD,*
Hani N. Sabbah, PHD, FACC,† Morton J. Kern, MD, FACC,‡ John Teerlink, MD, FACC,§
Robert O. Bonow, MD, FACC,* Mihai Gheorghiade, MD, FACC*
Chicago, Illinois; Detroit, Michigan; and Irvine and San Francisco, California
Acute heart failure syndromes (AHFS), with a high post-discharge mortality and rehospitalization rate, represent
a significant public health burden. The treatment of patients hospitalized with AHFS often includes the use of
vasoactive medications such as inotropes and vasodilators. Although such agents are frequently used, their
safety and efficacy remain controversial. A significant number of patients with heart failure have underlying cor-
onary artery disease and may be at greater risk from hemodynamic alterations that can diminish coronary perfu-
sion. In AHFS, the relationship among vasoactive medications, coronary perfusion, and potential myocardial in-
jury needs further investigation. Newer techniques now available to evaluate coronary perfusion should provide
guidance for the evaluation of existing and future vasoactive therapies for AHFS. (J Am Coll Cardiol 2008;52:
13–6) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.037m
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icute heart failure syndromes (AHFS) can be defined as a
apid or gradual change in heart failure signs and symptoms
hat necessitates urgent therapy (1). In spite of the apparent
nitial improvement with in-hospital therapies, the post-
ischarge event rates (mortality and rehospitalization) can
e as high as 30% to 50% (2). The available data suggest
hat vasoactive agents given for less than 24 to 48 h may
ncrease post-discharge mortality, particularly in patients
ith coronary artery disease (CAD) who develop drug-
elated hypotension (3,4). This may be due in part to a
ecrease in coronary perfusion leading to myocardial injury.
he assessment of coronary perfusion, however, has to date
ot been included in the evaluation of vasoactive drug
herapies for AHFS.
ackground
athophysiology of AHFS and myocardial injury. The
athophysiology of AHFS is complex. Coronary artery
isease is the most significant disease state in patients
ith AHFS (5), and these patients have a worse prog-
osis than patients with nonischemic etiologies (6). The
HRISTMAS (Carvedilol Hibernation Reversible Isch-
emia Trial) reported that 60% of patients with heart failure
nd CAD had hibernating myocardium (7). Hibernating
rom the *Feinberg School of Medicine, Northwestern University, Chicago, Illinois;
Henry Ford Health System, Detroit, Michigan; ‡University of California, Irvine,
alifornia; and the §University of California, San Francisco, California.F
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008, accepted March 24, 2008.yocardium is at risk for injury when confronted with the
emodynamic alterations seen in patients with AHFS.
hese changes include increased left ventricular filling
ressures, hypotension, and increased contractility in re-
ponse to vasoactive medications (8). These changes, to-
ether with further neurohormonal activation, result in
orsening endothelial dysfunction and may create a “perfect
torm” of myocardial injury (1).
Schulz et al. (9) demonstrated in an experimental
odel that increasing myocardial contractility in hiber-
ating myocardium by a brief infusion of low-dose
obutamine can lead to myocardial necrosis. Addition-
lly, in the PRESERVD-HF (Pilot Randomized Study of
esiritide Versus Dobutamine in Heart Failure) trial, the
ajority of patients presenting with AHFS and a history of
AD (in whom acute coronary syndrome was not suspected
linically) had a troponin release suggesting myocardial
njury (10).
The OPTIME-CHF (Outcomes of a Prospective Trial of
ntravenous Milrinone for Exacerbations of Chronic Heart
ailure) study randomized patients admitted with AHFS and
educed left ventricular ejection fraction to placebo or milri-
one. The 48-h infusion of milrinone was associated with a
5% increase in post-discharge mortality in patients with
AD who developed infusion-related hypotension (3). It
an be postulated that a decrease in blood pressure and
oronary perfusion secondary to milrinone contributed to
ncreased mortality as a result of myocardial injury.
In the ESCAPE (Evaluation Study of Congestive Heart
ailure and Pulmonary Artery Catheterization Effective-
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with inotropes, but not vasodila-
tors, was associated with an in-
creased post-discharge mortality
rate (11). The results of ES-
CAPE are particularly pertinent,
as this trial enrolled high-risk
patients, who are often consid-
ered to benefit the most from
vasoactive therapies.
Vasoactive medications and
coronary perfusion in AHFS.
Maintenance of coronary perfu-
sion may play an important role
in preventing myocardial injury
in AHFS (8). Coronary perfu-
sion is dependent on both epicar-
dial coronary artery blood flow
and microvascular flow. Under
normal physiological conditions,
oronary perfusion pressure and coronary vasoactive tone act
n concert to optimize coronary blood flow and achieve a
upply-demand balance (autoregulation) (12). In AHFS
nd CAD, autoregulation may become exhausted, with
oronary blood flow becoming totally dependent on sys-
emic pressure.
Vasoactive medications that are known to affect cardiac
unction, such as nitroprusside, nesiritide, dobutamine,
opamine, and milrinone, may cause a supply-demand
ismatch by increasing contractility and/or heart rate while
imultaneously decreasing blood pressure. The resultant
ecrease in coronary perfusion may lead to myocardial
njury. This may explain why the short-term use of these
edications in AHFS, particularly in patients with CAD,
an temporarily improve hemodynamics and symptoms
hile increasing post-discharge mortality (13).
Because these therapies have the potential to cause harm,
t is imperative to use them in a manner that leads to
mproved hemodynamics without causing myocardial injury
14). An improved understanding of the degree to which
urrent and future heart failure therapies affect coronary
erfusion may help differentiate protective strategies from
etrimental ones. Until now, however, accurate and repro-
ucible techniques for assessing coronary perfusion (taking
nto account both epicardial flow and microcirculation) have
een lacking.
ssessment of Coronary Perfusion
nvasive assessment of coronary perfusion. Coronary
ow reserve (CFR) is one traditional method that has been
sed to assess coronary perfusion. It is calculated as the ratio
f maximal blood velocity (during hyperemia) to resting
lood velocity for a given coronary artery.
In chronic heart failure, resting coronary blood flow
Abbreviations
and Acronyms
AHFS  acute heart failure
syndromes
CAD  coronary artery
disease
CFR  coronary flow
reserve
FFR  fractional flow
reserve
HSR  hyperemic stenosis
resistance
IMR  index of
microcirculatory resistance
rCFR  relative coronary
flow reserve
SPECT  single-photon
emission computed
tomographymeasured using velocity-encoded cine magnetic resonance Imaging) appears to be reduced in primary but not ischemic
ardiomyopathy. Coronary flow reserve, however, is com-
romised irrespective of etiology (15,16). The technique of
FR is somewhat limited in that when abnormal, it is
nclear whether the culprit lies in the epicardial arteries,
rterioles, or capillaries (as CFR decreases with increased
esistance at any level of the coronary circulation). Further-
ore, CFR can be altered by changes in baseline or
tress-induced flow, which are influenced by loading con-
itions, hemodynamics, and contractility (17). To overcome
his limitation, Gould et al. (18) proposed the concept of
elative CFR (rCFR), defined as the ratio of maximal flow
n a coronary artery with stenosis to maximal flow in a
oronary artery without stenosis (requires the interrogation
f an additional coronary vessel). This technique is of
imited value in patients with multivessel CAD, as there is
o “normal” vessel available for comparison. Moreover,
CFR relies on the assumption that microcirculatory resis-
ance is uniformly distributed, which is not the case in
atients with a prior history of myocardial infarction,
egional left ventricular dysfunction, myocardial fibrosis, or
symmetric hypertrophy (17).
To better quantify coronary perfusion at the epicardial
evel, Pijls et al. (19) introduced the concept of fractional
ow reserve (FFR), defined as the ratio of the mean distal
oronary artery pressure to the aortic pressure during max-
mal vasodilatation. The normal value of the index is 1.0,
ith the threshold for ischemia being 0.75, which corre-
ates with ischemia detected by noninvasive stress testing.
he main limitation of this technique is that it is unable to
ssess perfusion of the microcirculation.
With new advances in sensor guidewire technology,
ombined pressure (pressure sensor at tip of wire) and flow
measured by Doppler velocity or thermodilution) values
an now be calculated (20,21). Thermodilution measure-
ents can be used to calculate CFR (20). However, the
ame limitations that apply to traditional measurements of
FR exist with this technique as well.
Meuwissen et al. (21) improved on this technique by
eveloping a hyperemic stenosis resistance (HSR) index,
alculated as (mean aortic pressure – mean distal coronary
ressure)/average peak velocity at hyperemia (Doppler ve-
ocity). This allows for the separate assessment of microvas-
ular resistance, independent of stenoses at the epicardial
evel. In a fashion similar to FFR, HSR has a normal
eference value (HSR  0) and is largely independent of
emodynamic changes.
More recently, Fearon et al. (22) described the index of
icrocirculatory resistance (IMR) calculated by dividing
istal coronary pressure by the inverse of the hyperemic
ean transit time (thermodilution). The main advantage of
he IMR is that it is again independent of resistance in the
picardial artery and (unlike CFR) is less affected by
ariations in hemodynamic parameters such as blood pres-
ure and heart rate. Ng et al. (23) have validated the use of
MR in the cardiac catheterization laboratory. The main
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July 1, 2008:13–6 Heart Failure Syndromes and Coronary Perfusionifference between the HSR and IMR techniques lies in the
ype of wire used (Doppler wire vs. thermodilution), a
ecision that likely will be based on the comfort and
xperience of the operator.
Compared to CFR, both FFR (at the epicardial level) and
SR/IMR (microcirculation) were highly reproducible and
argely independent of hemodynamic perturbations. The
imultaneous measurement of FFR together with HSR or
MR is now capable of providing a simple and accurate
eans of assessing coronary perfusion across the entire
irculatory tree.
oninvasive assessment of coronary perfusion. Myocar-
ial perfusion imaging with single-photon emission com-
uted tomography (SPECT) remains the most widely used
echnique for the clinical evaluation of myocardial perfu-
ion, but clinical SPECT images are scaled to the most
ntense area of uptake in the ventricular myocardium (24).
his enables semiquantitative assessment of relative re-
ional myocardial blood flow but does not allow quantifi-
ation of absolute regional blood flow or myocardial perfu-
ion reserve.
Coronary flow velocity can also be measured by trans-
horacic Doppler echocardiography at rest and during
harmacologic vasodilation to calculate CFR (25). Al-
hough this technique is usually limited to the left
nterior descending coronary artery, its low cost and
ortability are clear advantages.
Positron emission tomography has become the pre-
erred technique for more sensitive and accurate perfu-
ion analysis. Quantitative measurements of myocardial
ow per unit weight (i.e., ml/min/g) can be derived from
erfusion imaging studies. Myocardial perfusion reserve
an then be calculated from measurements obtained at
est and during hyperemic stress (26). Widespread clin-
cal application has been slowed by limited access to
ositron emission tomography facilities and cyclotron-
roduced radiopharmaceuticals.
Absolute myocardial blood flow can also be measured by
rst-pass cardiac magnetic resonance perfusion imaging
27). Cardiac magnetic resonance perfusion imaging has a
igher spatial resolution than nuclear perfusion techniques,
llowing visualization of subendocardial perfusion abnor-
alities (28). This unique characteristic may be particularly
dvantageous for investigating AHFS because the subendo-
ardium is the first region to be affected by perturbations in
yocardial blood flow.
Another advantage of magnetic resonance imaging is
hat it allows for viability analysis. Patients with AHFS
ften harbor viable but noncontractile myocardium sec-
ndary to chronic ischemia (hibernating myocardium).
s observed by Schultz et al. (9) in their animal model,
nfusion of dobutamine is associated with necrosis of
ibernating myocardium. Cardiac viability imaging with
agnetic resonance imaging provides an accurate, high-
esolution method for detecting myocardial necrosis.
his may be particularly valuable in evaluating inotropes
nr vasodilators and monitoring for their potential detri-
ental effects in AHFS (29).
uture Perspectives
or Coronary Perfusion Assessment
he accurate assessment of coronary perfusion remains a
ifficult task, mainly because of the complexities involved in
he quantification of perfusion at the microvascular level.
he methods described earlier by Meuwissen et al. (21) and
earon et al. (22) represent novel techniques for the assess-
ent of coronary microcirculation. These techniques can
ow be readily and easily applied in the catheterization
aboratory and, when combined with additional measures
uch as FFR, provide accurate and reproducible information
oncerning the functional status of the entire coronary
irculation. Future research is needed to explore the role of
istal pressure and coronary flow velocity and to couple the
ssessment of microvascular resistance with clinical outcomes.
arger human clinical trials are needed to establish the accu-
acy and reproducibility of invasive IMR and HSR measure-
ents, as well as noninvasive methodologies to assess
erfusion and myocardial viability. As these methods and
echnologies evolve, future trials will provide clinical rele-
ance to the assessment of coronary perfusion in patients
dmitted to the hospital with AHFS. Furthermore, pre-
linical studies must be encouraged to explore the effects of
urrently used drugs as well as novel drugs on coronary
erfusion and on dysfunctional but viable myocardium.
onclusions
valuation of coronary perfusion promises to become an
mportant component in determining clinical outcomes in
atients with AHFS. Certain vasoactive agents used routinely
n heart failure therapy, although successful in improving the
emodynamic profiles of patients, have been linked to higher
ates of mortality. The exact mechanisms behind these findings
till need to be elucidated but may be related to myocardial
njury worsened by the impact of vasoactive medications and
nderlying disease states such as CAD. New methods of
ssessing and monitoring coronary perfusion may help to
larify the pathophysiology underlying these processes, as well
s to identify patients who may be at greater risk from these
herapies. Given the recent advances and improved techniques
both invasive and noninvasive) for the evaluation of coronary
erfusion, this information should now begin to be used as part
f the assessment of existing heart failure medications, as well
s for the development of novel therapies in the future.
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